Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC) - Hussain, M HA; Powles, T; Albers, P
; abgerufen am 5.6.2020